RxDoctor Payments Data

Reid Christopher, MD

Internal Medicine · Bessemer, ALNPI 1609978964

Payments from drug & device makers

$3,556in general payments, 2019–2025

Across 193 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$987
  • Amgen$403
  • Esperion Therapeutics, Inc.$382
  • Novartis$357
  • GSK$352
  • Pfizer$197
  • plus $878 from 15 others

What the payments were for

  • Food & beverage$3,45997%
  • Education$973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,556 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$81,103
Medicare patients
590
Services billed
1,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab345$243,981
OzempicSemaglutide203$217,294
MounjaroTirzepatide133$148,117
EliquisApixaban125$106,864
XareltoRivaroxaban61$55,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$42,488
JardianceEmpagliflozin43$39,958
Ezetimibe1,709$39,485
JanuviaSitagliptin Phosphate34$32,439
Tresiba Flextouch U-100Insulin Degludec60$31,547
Rosuvastatin Calcium1,287$25,170
LinzessLinaclotide28$21,851
Icosapent Ethyl61$21,073
TrintellixVortioxetine Hydrobromide22$20,284
TrulicityDulaglutide21$20,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$987$217,294203 claims
Lilly USA, LLCMounjaro, Trulicity$146$168,227154 claims
PfizerEliquis$197$106,864125 claims
Johnson & JohnsonXarelto$82$55,76361 claims
GSKTrelegy Ellipta, Anoro Ellipta$352$54,65167 claims
AbbVieLinzess$46$21,85128 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$136$20,28422 claims
AstraZenecaFarxiga, Symbicort$98$18,61331 claims
Esperion Therapeutics, Inc.Nexlizet$382$13,00724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Bessemer

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →